Table of Contents
Chapter 1. Global Ophthalmic Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer's Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
Chapter 2. Executive Summary
2.1. Global Ophthalmic Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Class
2.3.2. By Product Type
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Global Ophthalmic Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Global Ophthalmic Drugs Market Industry Analysis
4.1.1. Porter's 5 Force Model
4.1.2. Bargaining Power of Suppliers
4.1.3. Bargaining Power of Buyers
4.1.4. Threat of New Entrants
4.1.5. Threat of Substitutes
4.1.6. Competitive Rivalry
4.1.7. Futuristic Approach to Porter's 5 Force Model
4.1.8. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Ophthalmic Drugs Market Size & Forecasts by Drug Class 2022-2032
5.1. Anti-glaucoma Drugs
5.2. Dry Eye Drugs
5.3. Ophthalmic Anti-allergy/Inflammatory
5.4. Retinal Drugs
5.5. Anti-infective Drugs
5.6. Other Drugs
Chapter 6. Global Ophthalmic Drugs Market Size & Forecasts by Product Type 2022-2032
6.1. OTC Drugs
6.2. Prescription Drugs
Chapter 7. Global Ophthalmic Drugs Market Size & Forecasts by Region 2022-2032
7.1. North America Ophthalmic Drugs Market
7.1.1. U.S. Ophthalmic Drugs Market
7.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
7.1.1.2. Product Type breakdown size & forecasts, 2022-2032
7.1.2. Canada Ophthalmic Drugs Market
7.2. Europe Ophthalmic Drugs Market
7.2.1. U.K. Ophthalmic Drugs Market
7.2.2. Germany Ophthalmic Drugs Market
7.2.3. France Ophthalmic Drugs Market
7.2.4. Spain Ophthalmic Drugs Market
7.2.5. Italy Ophthalmic Drugs Market
7.2.6. Rest of Europe Ophthalmic Drugs Market
7.3. Asia-Pacific Ophthalmic Drugs Market
7.3.1. China Ophthalmic Drugs Market
7.3.2. India Ophthalmic Drugs Market
7.3.3. Japan Ophthalmic Drugs Market
7.3.4. Australia Ophthalmic Drugs Market
7.3.5. South Korea Ophthalmic Drugs Market
7.3.6. Rest of Asia Pacific Ophthalmic Drugs Market
7.4. Latin America Ophthalmic Drugs Market
7.4.1. Brazil Ophthalmic Drugs Market
7.4.2. Mexico Ophthalmic Drugs Market
7.4.3. Rest of Latin America Ophthalmic Drugs Market
7.5. Middle East & Africa Ophthalmic Drugs Market
7.5.1. Saudi Arabia Ophthalmic Drugs Market
7.5.2. South Africa Ophthalmic Drugs Market
7.5.3. Rest of Middle East & Africa Ophthalmic Drugs Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Pfizer Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Alcon Inc.
8.3.3. Novartis AG
8.3.4. Bausch Health Companies Inc.
8.3.5. Merck & Co., Inc.
8.3.6. Regeneron Pharmaceuticals Inc.
8.3.7. Allergan plc
8.3.8. Bayer AG
8.3.9. Genentech, Inc.
8.3.10. Nicox SA
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes